{"id":7189,"date":"2013-06-04T05:09:28","date_gmt":"2013-06-04T09:09:28","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7189"},"modified":"2013-06-04T05:09:28","modified_gmt":"2013-06-04T09:09:28","slug":"chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189","title":{"rendered":"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had surged by 22.28 percent to close at $2.36 per share for the end of last trading session on Monday. The shares of the pharmaceutical company had been trading in the range of $1.95 to $2.49 per share during the day. With the recent surge in prices, the shares of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had hit new 52 week high price level at $2.49 per share and the 52 week low price level of the company is at $0.70 per share.<\/p>\n<p style=\"text-align: justify;\">Chelsea Therapeutics International Limited (NASDAQ:CHTP) is in the development stage of the sector and is engaged in the research, development and commercialization of treatment therapies for wide range of human diseases. In the recently held Annual Deutsche Bank Health Conference, Chelsea Therapeutics International Limited (NASDAQ:CHTP) had presented a corporate update and an introduction to the development program of their product candidate Northera TM (droxidopa).<\/p>\n<p style=\"text-align: justify;\">Northera is one of the leading product candidates of Chelsea Therapeutics International Limited (NASDAQ:CHTP) which is presently in the Phase III of development stage. The drug is aimed at the treatment of neurogenic orthostatic hypotension in patients with Parkinson\u2019s disease, pure autonomic failure and multiple system atrophy.<\/p>\n<p style=\"text-align: justify;\">The shares of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had witnessed heavy trading volumes on Monday with nearly 6 million shares being exchanged hands, while the average trading volume for the company is at 552,559 share per day. The company presently holds 67.02 million shares outstanding in the market with 38 percent institutional ownership.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had surged by 22.28 percent to close at $2.36 per share for [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2438,2439],"stock_ticker":[],"class_list":["post-7189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-chelsea-therapeutics-international-limited-nasdaqchtp","tag-nasdaqchtp","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had surged by 22.28 percent to close at $2.36 per share for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-04T09:09:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage\",\"datePublished\":\"2013-06-04T09:09:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg\",\"keywords\":[\"Chelsea Therapeutics International Limited (NASDAQ:CHTP)\",\"NASDAQ:CHTP\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189\",\"name\":\"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg\",\"datePublished\":\"2013-06-04T09:09:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189","og_locale":"en_US","og_type":"article","og_title":"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage - Wall Street PR","og_description":"Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had surged by 22.28 percent to close at $2.36 per share for [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-04T09:09:28+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage","datePublished":"2013-06-04T09:09:28+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg","keywords":["Chelsea Therapeutics International Limited (NASDAQ:CHTP)","NASDAQ:CHTP"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189","url":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189","name":"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg","datePublished":"2013-06-04T09:09:28+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/large_glucose-insulin-supplies.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chelsea-therapeutics-international-limited-nasdaqchtp-in-phase-iii-development-stage-7189#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Chelsea Therapeutics International Limited (NASDAQ:CHTP) in Phase III development stage"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7189"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7189\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7190"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7189"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}